Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.59 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2025141 | 1.00 | DRD2 (0.59) | DRD2DRD3DRD4CHRM2CHRM1 | |
| SCHEMBL2024495 | 1.00 | DRD2 (0.59) | DRD2DRD3DRD4CHRM2CHRM1 | |
| SCHEMBL21244081 | 0.93 | DRD2 (0.68) | DRD2DRD3DRD4CHRM1 | |
| SCHEMBL7704484 | 0.93 | DRD2 (0.68) | DRD2DRD3DRD4CHRM1 | |
| SCHEMBL2022338 | 0.84 | DRD2 (0.56) | DRD2DRD3DRD4CHRM2CHRM1 | |
| SCHEMBL21244084 | 0.82 | DRD2 (0.67) | DRD2DRD3DRD4CHRM1 | |
| SCHEMBL21244085 | 0.82 | DRD2 (0.67) | DRD2DRD3DRD4CHRM1 | |
| SCHEMBL2023950 | 0.82 | DRD2 (0.57) | DRD2DRD3DRD4CHRM2CHRM1 | |
| SCHEMBL2022304 | 0.81 | DRD2 (0.51) | DRD2DRD3DRD4CHRM2CHRM1 | |
| SCHEMBL2020786 | 0.80 | DRD2 (0.74) | DRD2DRD3DRD4CHRM1HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516383-B1 | NEW AMINOTETRALINE DERIVATIVES | GMEINER PETER (DE) | 2017-05-03 | — | — | EP | disclosed |
| US-8691839-B2 | Aminotetraline derivatives | GMEINER PETER (DE) | 2014-04-08 | — | — | US | disclosed |
| US-20130331429-A1 | AMINOTETRALINE DERIVATIVES | GMEINER PETER (DE) | 2013-12-12 | — | — | US | disclosed |
| US-8586603-B2 | Aminotetraline derivatives | GMEINER PETER (DE) | 2013-11-19 | — | — | US | disclosed |
| US-20120277262-A1 | NEW AMINOTETRALINE DERIVATIVES | GMEINER PETER (DE) | 2012-11-01 | — | — | US | disclosed |
| EP-2516383-A1 | NEW AMINOTETRALINE DERIVATIVES | Gmeiner, Peter (DE) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076708-A1 | NEW AMINOTETRALINE DERIVATIVES | GMEINER PETER (DE) | 2011-06-30 | — | — | WO | disclosed |
| EP-2338873-A1 | New aminotetraline derivatives | Gmeiner, Peter (DE) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277262-A1 | NEW AMINOTETRALINE DERIVATIVES | AADAT, ABAT, AANAT | DRD2 946/4885DRD3 1150/4885DRD4 1001/4885 |
| US-20130331429-A1 | AMINOTETRALINE DERIVATIVES | AADAT, ABAT, SLC1A2 | DRD2 415/4885DRD3 673/4885DRD4 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.